Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Opioid Prescribing Guidelines Will Be More Template Than Commandment

Executive Summary

Commissioner Gottlieb says US FDA does not intend to force physicians to adhere to opioid prescribing guidelines being developed by National Academies of Sciences, Engineering, and Medicine.

You may also be interested in...



Nearly 9% FY 2019 Increase For FDA In Shutdown-Averting Appropriations Bill

Consolidated Appropriations Act gives FDA $5.58bn overall, 8.7% more than allocated in FY 2018. FDA received $268.8m in additional budget authority and $178.3m in additional user fee funds. FY 2019 funding would have lapsed Feb. 16 and another government shutdown would have started if President Trump didn't sign the bill on Feb. 15.

US FDA Wins Big In Shutdown-Averting Approps Bill

Agency would receive more than $268m in additional dollars for medical product and food safety as part of substantial FY 2019 increase.

US FDA Wants Opioid Prescribing Guidelines To Be Highly Specific, But It May Have To Compromise

National Academies of Sciences, Engineering, and Medicine committee meeting suggest it is difficult to write condition-specific guidelines for opioid prescribing in the primary care setting.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS124248

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel